Clinical trial
A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma
NCT01541332 is registered in ClinicalTrials.gov with Oncotherapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Oncotherapeutics
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- February 29, 2012
- Completion date
- December 31, 2016
- Enrollment
- 70 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.